Genetic Engineering News (Internet) 06/12/06 GlucoLight Corporation has announced that it will be presenting on Thursday, June 22, 2006, at 10:30 a.m. at Medtech Insight and Windhover Information's "In3 Medical Device Summit" Conference, June 21-23, 2006, at The Palace Hotel in San Francisco, Calif. GlucoLight Corporation, located in the Lehigh Valley, is privately funded. Five pilot studies (2004-2006) on healthy volunteer subjects and type 1 & 2 diabetic subjects have demonstrated the viability of the company's OCT based technology. Studies in pigs resuscitated from both blood loss and septic shock have shown the ability to closely track blood glucose levels in the hyperglycemic, fluid overloaded state that is typical of post-cardiac surgery and general intensive care patients. GlucoLight has substantial intellectual property (seven patent applications have been filed) and the company has executed an exclusive patent license agreement with the University of Texas Medical Branch at Galveston.